Brokerages expect that Healthequity Inc (NASDAQ:HQY) will announce earnings of $0.21 per share for the current quarter, Zacks reports. Eight analysts have made estimates for Healthequity’s earnings, with estimates ranging from $0.16 to $0.24. Healthequity posted earnings of $0.06 per share during the same quarter last year, which indicates a positive year over year growth rate of 250%. The firm is expected to issue its next quarterly earnings results after the market closes on Wednesday, February 6th.
On average, analysts expect that Healthequity will report full year earnings of $1.14 per share for the current financial year, with EPS estimates ranging from $1.09 to $1.18. For the next year, analysts forecast that the firm will report earnings of $1.32 per share, with EPS estimates ranging from $1.27 to $1.36. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of analysts that that provide coverage for Healthequity.
Healthequity (NASDAQ:HQY) last issued its quarterly earnings data on Tuesday, December 4th. The company reported $0.22 EPS for the quarter, beating the Zacks’ consensus estimate of $0.20 by $0.02. The firm had revenue of $70.50 million for the quarter, compared to analysts’ expectations of $69.60 million. Healthequity had a net margin of 24.52% and a return on equity of 12.42%. The firm’s revenue was up 24.1% on a year-over-year basis. During the same period in the prior year, the company earned $0.17 EPS.
Several equities research analysts have issued reports on the stock. BidaskClub raised shares of Healthequity from a “buy” rating to a “strong-buy” rating in a research note on Thursday, November 1st. Cantor Fitzgerald raised their price target on shares of Healthequity from $80.00 to $82.00 and gave the stock a “neutral” rating in a research note on Thursday, December 6th. SunTrust Banks cut shares of Healthequity from a “buy” rating to a “hold” rating and decreased their price target for the stock from $105.00 to $90.00 in a research note on Thursday, December 6th. ValuEngine lowered shares of Healthequity from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 5th. Finally, Zacks Investment Research lowered shares of Healthequity from a “buy” rating to a “hold” rating in a report on Tuesday, November 20th. Four investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $89.62.
In other Healthequity news, Director Frank Corvino sold 1,778 shares of the stock in a transaction that occurred on Monday, December 10th. The shares were sold at an average price of $67.78, for a total value of $120,512.84. Following the completion of the sale, the director now owns 5,051 shares of the company’s stock, valued at $342,356.78. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Darcy G. Mott sold 4,000 shares of the stock in a transaction that occurred on Tuesday, January 22nd. The shares were sold at an average price of $60.81, for a total transaction of $243,240.00. Following the completion of the sale, the vice president now directly owns 79,200 shares of the company’s stock, valued at approximately $4,816,152. The disclosure for this sale can be found here. Insiders sold 11,846 shares of company stock worth $751,308 in the last 90 days. 4.00% of the stock is currently owned by insiders.
A number of large investors have recently modified their holdings of HQY. FMR LLC grew its position in Healthequity by 26.5% in the second quarter. FMR LLC now owns 3,410,542 shares of the company’s stock valued at $256,132,000 after acquiring an additional 715,441 shares in the last quarter. Morgan Stanley grew its position in shares of Healthequity by 15.5% during the third quarter. Morgan Stanley now owns 4,001,425 shares of the company’s stock worth $377,775,000 after buying an additional 536,366 shares in the last quarter. Clearbridge Investments LLC grew its position in shares of Healthequity by 976,643.6% during the third quarter. Clearbridge Investments LLC now owns 380,930 shares of the company’s stock worth $35,964,000 after buying an additional 380,891 shares in the last quarter. Massachusetts Financial Services Co. MA acquired a new stake in shares of Healthequity during the fourth quarter worth approximately $15,455,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Healthequity during the third quarter worth approximately $19,021,000. 94.07% of the stock is owned by institutional investors.
NASDAQ HQY traded up $0.64 during trading hours on Thursday, reaching $77.74. The company’s stock had a trading volume of 333,953 shares, compared to its average volume of 964,259. The stock has a market cap of $4.81 billion, a price-to-earnings ratio of 143.96, a PEG ratio of 2.52 and a beta of 1.64. Healthequity has a fifty-two week low of $47.33 and a fifty-two week high of $101.58.
HealthEquity, Inc provides various solutions for managing health care accounts, health reimbursement arrangements, and flexible spending accounts for health plans, insurance companies, and third-party administrators in the United States. The company offers healthcare saving and spending platform, a cloud-based platform for individuals to make health saving and spending decisions, pay healthcare bills, compare treatment options and prices, receive personalized benefit and clinical information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.
Featured Story: Catch-Up Contributions
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Healthequity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healthequity and related companies with MarketBeat.com's FREE daily email newsletter.